Safety of neuraminidase inhibitors for influenza

Mark Jones*, Chis Del Mar

*Corresponding author for this work

Research output: Contribution to journalReview articleResearchpeer-review

14 Citations (Scopus)
164 Downloads (Pure)


Neuraminidase inhibitors, oseltamivir and zanamivir, are used for the treatment of, and protection from, influenza. The safety of these compounds has been assessed in systematic reviews. However, the data presented are somewhat limited by the paucity of good quality adverse event data available. The majority of safety outcomes are based on evidence from just one or two randomised controlled trials. The results of the systematic reviews suggest that neuraminidase inhibitors have a reasonable side effect and adverse effect profile if they are to be used to treat or protect patients against a life-threatening disease. However, if these compounds are to be prescribed in situations in which avoidance of inconvenience or minor discomfort is hoped for, then the balance of harms to benefits will be more difficult to judge.

Original languageEnglish
Pages (from-to)603-608
Number of pages6
JournalExpert Opinion on Drug Safety
Issue number5
Publication statusPublished - Sept 2006


Dive into the research topics of 'Safety of neuraminidase inhibitors for influenza'. Together they form a unique fingerprint.

Cite this